Vaccinate children now:Approval for use of covacin is likely to be obtained by September; Awaiting Phase-2-3 trial results

Vaccinate children now:Approval for use of covacin is likely to be obtained by September; Awaiting Phase-2-3 trial results



AIIMS Delhi and Patna are conducting Bharat Biotech covacin trial on children aged 2 to 17 years.

Also Read 
With 'Finger and Oil' on the canvas, the young artist earns Rs 2.5 lakh a year, creating paintings of many celebs.

Corona's indigenous vaccine covexin for children may be approved for use until September. In a report, AIIMS director Randeep Guleria expressed hope in this regard. Gularia said data on the Phase-2 and Phase-3 trials of the covacin vaccine on children would be available by September, during which time the vaccine for children could be approved.

Also Read 
These are the 8 mild and severe symptoms of Delta Plus, this variant can be fatal for the third wave.

Guleria says the Pfizer and Bioentech vaccines could be another option for these children if approved in India. Speaking of Corona's third wave, on the other hand, Guleria does not agree that children will be more affected by the third wave. He says there is no reason to believe this theory.

Also Read 
 Concerns around the world with the new variant

Guleria further said that now the school should be considered for opening, although care must be taken that the educational institution does not become a super spreader somewhere. For this Guleria advised that schools in the content zone could be opened one day by leaving one day. In addition, care must be taken to ensure that children follow the Kovid protocol.

Also Read 
Does burning cow dung and ghee really produce oxygen? Find out what the doctors said

Trials on children underway at Delhi, Patna AIIMS
Many experts said that children are most likely to be affected in the third wave in India. Vaccination preparations for children have been stepped up in these circumstances. Bharat Biotech's covacin trial is being conducted on children aged 2 to 17 in AIIMS Delhi and Patna. The Drugs Controller General of India (DGCI) had on May 12 approved the second and third phase trials for the children.

VWatch ideo

Cadillac's Zykov-D is also on trial with children
Cadila may apply to DCGI for Zykov-D's emergency approval this week. Data analysis of the phase-3 trial of the vaccine is almost ready. The company has informed the government about this. The vaccine is being tested on adults as well as children between the ages of 12 and 18. Presumably, the company may soon conduct a vaccine trial on children aged 5 to 12 years. Vaccination mortality can be increased if the trial results are good.